IL-7 earns her ticket in allo-HSCT

Abstract

In this issue of Blood, Perales and colleagues report the first trial of recombinant in recipients of T cell-depleted allogeneic hematopoietic stem cell transplantation (allo-HSCT) showing the safety of the drug and improvement in T-cell recovery1 (Figure Presented).